On p. 979 of the October 2002 issue (Nat. Biotechnol. 20, 977; 2002), the feature entitled “Seeking sweet relief for diabetes” incorrectly describes therapies being developed by Amylin Pharmaceuticals. Amylin has two late-stage, first-in-class diabetes drug candidates in development, SYMLIN (pramlintide acetate) and AC2993 (synthetic exendin-4). SYMLIN is a synthetic version of human amylin. SYMLIN has received an Approvable Letter from the FDA for type 1 and insulin-using type 2 diabetes. Amylin plans to submit an NDA amendment to the FDA in early 2003. Exendin-4, not amylin, is a protein found in the salivary secretions of the Gila monster and is the basis for Amylin's second diabetes drug candidate, AC2993. AC2993 shares many of the glucose regulating attributes of GLP-1 including glucose-dependent stimulation of insulin secretion. AC2993 is currently in Phase 3, with an NDA filing planned in 2004. Nature Biotechnology regrets the error.
The online version of the original article can be found at 10.1038/nbt1002-977